Search bioRxivSearch

Biology subjects

Molina-Porcel, L.

Publications and source records attributed to Molina-Porcel, L..

2 recordsLinked to original sources

Assessing circular RNAs in Alzheimer disease

Circular RNAs (circRNA) are evolutionary conserved non-coding RNAs resulting from the backsplicing of precursor messengers. Recently, a circular-transcriptome-wide study of circRNA in brain tissue from patients with Alzheimers disease (AD) has revealed a striking association between the expression of circRNA and AD pathological diagnosis. In the present study, we aimed at replicating the major findings in an independent case series comprising definitive sporadic and familial AD. In order to assess the specificity of circRNA changes, we also included cases with frontotemporal lobar degeneration (FTLD), comprising brain specimens with TDP-43 aggregates (FTLD-TDP43) and samples that presented Tau accumulation (FTLD-Tau). Through a quantitative PCR approach, we evaluated a total of eight circRNAs that surpassed the significant threshold in the former meta-analysis (circHOMER1, circDOCK1, circKCNN2, circMAN2A1, circFMN1, circRTN4, circMAP7, and circPICALM). Average expression changes between AD patients and controls followed the same directions as previously reported, suggesting an overall upregulation of circDOCK1, circMAP7, circMAN2A1, circRTN4 and circPICALM, and a downregulation of the remainder (circHOMER1, circFMN1 and circKCNN2) in AD brain tissue. We also confirmed an exacerbated alteration in circRNA expression in the Mendelian AD group compared to the sporadic forms. Two circRNAs, circHOMER1 and circKCNN2, also showed significant expression alterations in the group of FTLD-Tau and FTLD-TDP43, respectively. Overall, these results reinforce the conception that expression of circRNAs is altered in Alzheimers disease, and also suggest a wider involvement of this particular class of RNA in other neurodegenerative dementias.

genomics

Neuropathological validation of the MDS-PSP criteria with PSP and other frontotemporal lobar degeneration

BackgroundProgressive supranuclear palsy (PSP) is clinically heterogeneous. Clinical diagnostic criteria were revised in 2017, to increase sensitivity and operationalize the diagnosis of PSP Richardsons syndrome (PSP-RS) and \"variant\" syndromes (vPSP).\n\nObjectivesTo determine the (1) sensitivity and specificity of the 1996 NINDS-SPSP and 2017 MDS-PSP criteria; (2) false positive rates in frontotemporal dementia with frontotemporal lobar degeneration (FTLD); and (3) clinical evolution of variant PSP syndromes (vPSP).\n\nMethodsRetrospective multicenter review of 108 neuropathologically-confirmed PSP patients and 81 patients with other forms of FTLD: 38 behavioral variant frontotemporal dementia (bvFTD), 14 non-fluent/agrammatic variant primary progressive aphasia (nfvPPA), and 29 corticobasal degeneration (CBD), Sensitivity and specificity of the MDS-PSP criteria were compared to the NINDS-SPSP criteria at baseline. In a subset of cases, the timing and frequency of clinical features were compared across groups over six years.\n\nResultsSensitivity for recognition of probable and possible PSP pathology was higher by MDS-PSP criteria (72.2-100%) than NINDS-SPSP criteria (48.1-61.1%). Specificity was higher by NINDS-SPSP criteria (97.5-100%) than MDS-PSP criteria (53.1-95.1%). False positives by MDS-PSP criteria were few for bvFTD (10.5-18.4%) but common for CBD and nfvPPA (fulfilling \"suggestive of PSP). Most vPSP cases developed PSP-RS-like features within six years, including falls and supranuclear gaze palsy, distinguishing frontal presentations of PSP from bvFTD, and speech/language presentations of PSP from nfvPPA.\n\nConclusionsThe 2017 MDS-PSP criteria successfully identify PSP, including variant phenotypes. This independent validation of the revised clinical diagnostic criteria strengthens the case for novel therapeutic strategies against PSP to include variant presentations.

neuroscience